8 research outputs found
Validation-based insertional mutagenesis (VBIM) technology identifies adenomatous polypossis coli (APC) like protein (ALP) as a novel negative regulator of NF-κB
Colorectal cancer (CRC) is the third leading cause of cancer related deaths in the
United States. The nuclear factor κB (NF-κB) is an important family of
transcription factors whose aberrant activation has been found in many types of
cancer, including CRC. Therefore, understanding the regulation of NF-κB is of
ultimate importance for cancer therapy. Using a novel validation-based
insertional mutagenesis (VBIM) strategy, our lab has identified the novel
adenomatous polyposis coli (APC) like protein (ALP) gene as a negative
regulator of NF-κB. Preliminary studies from our lab demonstrated that
overexpression of ALP led to decreased NF-κB activity by κB reporter assay and
electrophoresis mobility gel shift assay (EMSA). The current project aims to
further evaluate the role of ALP in the regulation of NF-κB signaling in CRC cells.
We found that overexpression of ALP in human CRC HT29 cells greatly reduced
both the number and the size of colonies that were formed in a soft agar assay.
ALP overexpression also decreased the cell growth rate and cell migration ability,
while shRNA mediated knockdown of ALP showed opposite effects, confirming
that ALP is a tumor suppressor in CRC HT29 cells. Overexpression of ALP led to
decreased NF-κB activity by κB reporter assay and condition media assay in
CRC HT29 cells. Furthermore, immunohistochemical analysis with human colon vii
tissues revealed that there is a gradual loss of ALP protein with tumor
progression. We also found that ALP predominantly localizes in the cytoplasm,
and binds to the p65 subunit of NF-κB, and might be functioning downstream of
IκB kinase (IKK). In summary, in this study, we provide evidence regarding the
tumor suppressor role of ALP in CRC by functioning as novel negative regulator
of NF-κB. This discovery could lead to the establishment of ALP as a potential
biomarker and therapeutic target in CRC
Role of ChIP-seq in the discovery of transcription factor binding sites, differential gene regulation mechanism, epigenetic marks and beyond
Many biologically significant processes, such as cell differentiation and cell cycle progression, gene transcription and DNA replication, chromosome stability and epigenetic silencing etc. depend on the crucial interactions between cellular proteins and DNA. Chromatin immunoprecipitation (ChIP) is an important experimental technique for studying interactions between specific proteins and DNA in the cell and determining their localization on a specific genomic locus. In recent years, the combination of ChIP with second generation DNA-sequencing technology (ChIP-seq) allows precise genomic functional assay. This review addresses the important applications of ChIP-seq with an emphasis on its role in genome-wide mapping of transcription factor binding sites, the revelation of underlying molecular mechanisms of differential gene regulation that are governed by specific transcription factors, and the identification of epigenetic marks. Furthermore, we also describe the ChIP-seq data analysis workflow and a perspective for the exciting potential advancement of ChIP-seq technology in the future
Critical role of NF-κB in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, and in spite of intense efforts there are limited therapeutic options for patients with PDAC. PDACs harbor a high frequency of Kras mutations and other driver mutations that lead to altered signaling pathways and contribute to therapeutic resistance. Importantly, constitutive activation of nuclear factor κB (NF-κB) is frequently observed in PDAC. An increasing body of evidence suggests that both classical and non-classical NF-κB pathways play a crucial role in PDAC development and progression. In this review, we update the most recent advances regarding different aspects of NF-κB involvement in PDAC development and progression, emphasizing its potential as a therapeutic target and the need to discover pathway-specific cytosolic NF-κB regulators which could be used to design novel therapeutic strategies for PDAC
Genetic pathways, prevention, and treatment of sporadic colorectal cancer
Epithelial cancer of the colon and rectum, also known as colorectal cancer (CRC), results from a progressive accumulation of genetic and epigenetic alterations that lead to uncontrolled growth of colonocytes, the cells lining the colon and rectum. CRC is the second leading cause of cancer-related deaths and the third most common cancer in men and in women in the U.S. Of all the patients diagnosed with CRC every year, it is estimated that the vast majority of CRCs are non-hereditary "sporadic cancers" with no apparent evidence of an inherited component. Sporadic CRC results from the cumulative effects of multiple genetic and epigenetic alterations caused by somatic mutations, which may themselves be the indirect result of several environmental factors. This review examines our current understanding of the major genetic alterations leading to colon cancer, options for prevention and early detection of CRC, and the currently available treatment approaches that may target these different genetic alterations
Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF- B in colon cancer
poster abstractY-box binding protein 1 (YBX1) is a multifunctional protein known to facilitate many of
the hallmarks of cancer. Elevated levels of YBX1 protein are highly correlated with
cancer progression, making it an excellent marker in cancer. The connection between
YBX1 and the important nuclear factor B (NF-B), has never been previously reported.
Here, we show that overexpression of wild type YBX1 (wtYBX1) activates NF-B,
suggesting that YBX1 is a potential NF-B activator. Furthermore, using mass
spectrometry analysis, we identified novel phosphorylation of serine 165 (S165) on
YBX1. Overexpression of the S165A-YBX1 mutant in either 293 cells or colon cancer
HT29 cells showed dramatically reduced NF-B activating ability as compared to that of
wtYBX1, confirming that S165 phosphorylation is critical for the activation of NF-B by
YBX1. We further show that expression of the S165A-YBX1 mutant dramatically
decreased the expression of NF-B-inducible genes, reduced cell growth, and
compromised tumorigenic ability as compared to wtYBX1. Taken together, we provide
the first evidence that YBX1 functions as a tumor promoter via NF-B activation, and
phosphorylation of S165 of YBX1 is critical for this function. Therefore, our important
discovery may lead to blocking S165 phosphorylation as a potential therapeutic strategy
to treat colon cancer
Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer.
Y-box binding protein 1 [YBX1] is a multifunctional protein known to facilitate many of the hallmarks of cancer. Elevated levels of YBX1 protein are highly correlated with cancer progression, making it an excellent marker in cancer. The connection between YBX1 and the important nuclear factor κB [NF-κB] has never been reported. Here, we show that overexpression of wild type YBX1 [WT-YBX1] activates NF-κB, suggesting that YBX1 is a potential NF-κB activator. Furthermore, using mass spectrometry analysis we identified novel phosphorylation of serine 165 [S165] on YBX1. Overexpression of the S165A-YBX1 mutant in either HEK293 cells or colon cancer HT29 cells showed dramatically reduced NF-κB activating ability as compared with that of WT-YBX1, confirming that S165 phosphorylation is critical for the activation of NF-κB by YBX1. We also show that expression of the S165A-YBX1 mutant dramatically decreased the expression o
Using VBIM Technique to Discover ARMC4/ODAD2 as a Novel Negative Regulator of NF-κB and a New Tumor Suppressor in Colorectal Cancer
Since nuclear factor (NF) κB plays pivotal roles in inflammation and cancer, understanding its regulation holds great promise for disease therapy. Using the powerful validation-based insertional mutagenesis (VBIM) technique established by us previously, we discovered armadillo repeat-containing protein 4 (ARMC4)/outer dynein arm docking complex subunit 2 (ODAD2), a rarely studied protein known to date, as a novel negative regulator of NF-κB in colorectal cancer (CRC). High expression of ARMC4 downregulated the expression of NF-κB-dependent genes, dramatically reduced NF-κB activity, cellular proliferation, anchorage-independent growth, and migratory ability in vitro, and significantly decreased xenograft tumor growth in vivo. Co-immunoprecipitation experiments demonstrated that ARMC4 forms a complex with NF-κB. Importantly, the lower ARMC4 expression in patient tumors than normal tissues indicates its potential tumor suppressor function in CRC. Collectively, we uncovered a completely new facet of ARMC4 function by identifying it as a novel NF-κB negative regulator, thus uncovering ARMC4 as a potential new therapeutic target in CRC